» Articles » PMID: 35322119

Alginate Oligosaccharides Enhance Diffusion and Activity of Colistin in a Mucin-rich Environment

Overview
Journal Sci Rep
Specialty Science
Date 2022 Mar 24
PMID 35322119
Authors
Affiliations
Soon will be listed here.
Abstract

In a number of chronic respiratory diseases e.g. cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD), the production of viscous mucin reduces pulmonary function and represents an effective barrier to diffusion of inhaled therapies e.g. antibiotics. Here, a 2-compartment Transwell model was developed to study impaired diffusion of the antibiotic colistin across an artificial sputum (AS) matrix/medium and to quantify its antimicrobial activity against Pseudomonas aeruginosa NH57388A biofilms (alone and in combination with mucolytic therapy). High-performance liquid chromatography coupled with fluorescence detection (HPLC-FLD) revealed that the presence of AS medium significantly reduced the rate of colistin diffusion (> 85% at 48 h; p < 0.05). Addition of alginate oligosaccharide (OligoG CF-5/20) significantly improved colistin diffusion by 3.7 times through mucin-rich AS medium (at 48 h; p < 0.05). Increased diffusion of colistin with OligoG CF-5/20 was shown (using confocal laser scanning microscopy and COMSTAT image analysis) to be associated with significantly increased bacterial killing (p < 0.05). These data support the use of this model to study drug and small molecule delivery across clinically-relevant diffusion barriers. The findings indicate the significant loss of colistin and reduced effectiveness that occurs with mucin binding, and support the use of mucolytics to improve antimicrobial efficacy and lower antibiotic exposure.

Citing Articles

How Three Self-Secreted Biofilm Exopolysaccharides of , Psl, Pel, and Alginate, Can Each Be Exploited for Antibiotic Adjuvant Effects in Cystic Fibrosis Lung Infection.

Chung J, Eisha S, Park S, Morris A, Martin I Int J Mol Sci. 2023; 24(10).

PMID: 37240055 PMC: 10218432. DOI: 10.3390/ijms24108709.


Recent advances in therapeutic targets identification and development of treatment strategies towards Pseudomonas aeruginosa infections.

Sanya D, Onesime D, Vizzarro G, Jacquier N BMC Microbiol. 2023; 23(1):86.

PMID: 36991325 PMC: 10060139. DOI: 10.1186/s12866-023-02832-x.


Innovative Strategies to Overcome Antimicrobial Resistance and Tolerance.

Choudhary M, Romling U, Nadeem F, Bilal H, Zafar M, Jahan H Microorganisms. 2023; 11(1).

PMID: 36677308 PMC: 9863313. DOI: 10.3390/microorganisms11010016.

References
1.
Muller L, Murgia X, Siebenburger L, Borger C, Schwarzkopf K, Sewald K . Human airway mucus alters susceptibility of Pseudomonas aeruginosa biofilms to tobramycin, but not colistin. J Antimicrob Chemother. 2018; 73(10):2762-2769. DOI: 10.1093/jac/dky241. View

2.
Eljaaly K, Bidell M, Gandhi R, Alshehri S, Enani M, Al-Jedai A . Colistin Nephrotoxicity: Meta-Analysis of Randomized Controlled Trials. Open Forum Infect Dis. 2021; 8(2):ofab026. PMC: 7888569. DOI: 10.1093/ofid/ofab026. View

3.
Sanders N, De Smedt S, Van Rompaey E, Simoens P, De Baets F, Demeester J . Cystic fibrosis sputum: a barrier to the transport of nanospheres. Am J Respir Crit Care Med. 2000; 162(5):1905-11. DOI: 10.1164/ajrccm.162.5.9909009. View

4.
Falavigna M, Stein P, Flaten G, di Cagno M . Impact of Mucin on Drug Diffusion: Development of a Straightforward in Vitro Method for the Determination of Drug Diffusivity in the Presence of Mucin. Pharmaceutics. 2020; 12(2). PMC: 7076515. DOI: 10.3390/pharmaceutics12020168. View

5.
Pritchard M, Powell L, Menzies G, Lewis P, Hawkins K, Wright C . A New Class of Safe Oligosaccharide Polymer Therapy To Modify the Mucus Barrier of Chronic Respiratory Disease. Mol Pharm. 2016; 13(3):863-72. DOI: 10.1021/acs.molpharmaceut.5b00794. View